Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo OTCs, Nutritionals Underperform Despite Record Overall Revenue

This article was originally published in The Tan Sheet

Executive Summary

Perrigo delivered record first-quarter revenue but fell short of analyst expectations due to slowing growth in its consumer health care and nutritional units.

You may also be interested in...



Perrigo Campaigns For Rational OTC Shopping Over Brand Loyalty

The online “Store Brand Meds” campaign launched by Perrigo in early 2013 encourages consumers to “Make store brands your brand,” by emphasizing lower price points and equivalent active ingredients. Overcoming consumer connections to brands such as Tylenol is a challenge, however.

Perrigo Campaigns For Rational OTC Shopping Over Brand Loyalty

The online “Store Brand Meds” campaign launched by Perrigo in early 2013 encourages consumers to “Make store brands your brand,” by emphasizing lower price points and equivalent active ingredients. Overcoming consumer connections to brands such as Tylenol is a challenge, however.

In Brief

GSK comments on nicotine’s status; Perrigo launches formula; NAI sales up with licensing revenue; Japanese star anise is adulterant; POMx for sale; toothpaste nurdle suit settled; Virility Max recalled

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel